Piper Sandler analyst Biren Amin assumes coverage on Regeneron Pharma (NASDAQ: REGN) with a Overweight rating and a price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage